Making in 2025. Grail Inc. (NASDAQ:GRAL) is one of the top performers. Grail Inc. soared by 379.5 percent in 2025, with the ...

Shares of Grail have quintupled this year to nearly $90, as investors waited for news about the Pathfinder 2 study of its cancer-detecting blood test. Management hinted this summer the numbers were ...

Early-stage cancer detection startup Grail, which has investors including Amazon CEO Jeff Bezos, has filed to go public, according to a Sept. 9 CNBC report. 1. DNA-sequencing machine developer ...

More than 67,000 Americans are expected to be diagnosed with pancreatic cancer this year, but a new blood test is offering ...

CHICAGO -- Hundreds of people using the test company Grail were wrongly told they might have cancer, the company said in a statement Monday. Grail said a software glitch related to their telemedicine ...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings from the PATHFINDER study of ...

MENLO PARK, Calif., April 22, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the ...

MENLO PARK, Calif., Oct. 17, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive ...

MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with ...

Galleri Accurately Predicted the Location of the Cancer in Almost All Cases Initially Considered as False Positives, Reinforcing the Value of Galleri's CSO Capability MENLO PARK, Calif. and OXFORD, ...